Karvea (Irbesartan)
Angiotensin II Receptor Blocker for Hypertension and Diabetic Nephropathy
Quick Facts About Karvea
Key Takeaways About Karvea
- Effective blood pressure control: Irbesartan provides sustained 24-hour blood pressure reduction with once-daily dosing, reducing the risk of stroke, heart attack, and heart failure
- Kidney protection in diabetes: Karvea is specifically indicated to slow the progression of kidney disease in patients with type 2 diabetes and hypertension
- Lower cough risk than ACE inhibitors: ARBs like irbesartan cause significantly less dry cough compared to ACE inhibitors, making them a well-tolerated alternative
- Contraindicated in pregnancy: Karvea must not be used during pregnancy as it can cause serious harm to the developing foetus, particularly during the second and third trimesters
- Monitor potassium levels: Irbesartan can raise blood potassium levels (hyperkalaemia), especially in patients with kidney impairment or those taking potassium supplements
What Is Karvea and What Is It Used For?
Karvea (irbesartan) is an angiotensin II receptor blocker (ARB) that works by blocking the AT1 receptor, preventing angiotensin II from constricting blood vessels and stimulating aldosterone release. It is prescribed for the treatment of essential hypertension and for the protection of the kidneys in patients with type 2 diabetes mellitus who also have high blood pressure.
Karvea belongs to a class of medications known as angiotensin II receptor blockers, commonly abbreviated as ARBs or sartans. The renin-angiotensin-aldosterone system (RAAS) plays a central role in regulating blood pressure and fluid balance. When blood pressure drops or sodium levels fall, the kidneys release renin, which triggers a cascade that ultimately produces angiotensin II – a potent vasoconstrictor. By selectively blocking the AT1 receptor, irbesartan prevents angiotensin II from exerting its blood pressure-raising and aldosterone-stimulating effects.
The primary indications for Karvea are the treatment of essential hypertension (high blood pressure without an identifiable secondary cause) and the treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive treatment regimen. In the landmark IDNT (Irbesartan Diabetic Nephropathy Trial) study, irbesartan 300 mg daily was shown to reduce the risk of doubling of serum creatinine by 33% and end-stage renal disease by 23% compared with placebo, independent of its blood pressure-lowering effect.
High blood pressure is a major risk factor for cardiovascular disease, including heart attack, stroke, heart failure, and chronic kidney disease. The World Health Organization (WHO) estimates that approximately 1.28 billion adults worldwide have hypertension, with fewer than half receiving adequate treatment. ARBs like irbesartan are recommended as first-line therapy for hypertension by major international guidelines, including the European Society of Cardiology/European Society of Hypertension (ESC/ESH) 2023 guidelines and the American Heart Association/American College of Cardiology (AHA/ACC) guidelines.
Irbesartan is generally well tolerated and has a favourable side effect profile compared with some other antihypertensive classes. Unlike ACE inhibitors, which block the enzyme that produces angiotensin II, ARBs block the receptor where angiotensin II acts. This mechanistic difference means that ARBs do not inhibit the breakdown of bradykinin, a peptide that is responsible for the dry, persistent cough seen in approximately 5–20% of patients taking ACE inhibitors. For this reason, Karvea is often prescribed as an alternative for patients who cannot tolerate ACE inhibitors due to cough.
Mechanism of Action
Irbesartan is a non-peptide, selective antagonist of the angiotensin II type 1 (AT1) receptor. It blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, the adrenal gland, and other tissues. This results in vasodilation (relaxation of blood vessels), reduced aldosterone secretion, decreased sodium and water retention, and ultimately lower blood pressure. The AT2 receptor, which is thought to mediate potentially beneficial effects such as vasodilation and anti-proliferation, remains unblocked.
After oral administration, irbesartan is rapidly absorbed with an absolute bioavailability of approximately 60–80%. Peak plasma concentrations are reached within 1.5 to 2 hours. Food does not significantly affect the bioavailability of irbesartan, so it can be taken with or without meals. The terminal elimination half-life is 11 to 15 hours, supporting effective once-daily dosing. Irbesartan is primarily metabolised by the cytochrome P450 enzyme CYP2C9 and is excreted through both the faeces (approximately 80%) and urine (approximately 20%).
What Should You Know Before Taking Karvea?
Before starting Karvea, it is essential to inform your doctor about all existing medical conditions, particularly kidney disease, liver disease, heart conditions, diabetes, and dehydration. Karvea is strictly contraindicated during pregnancy and must not be combined with aliskiren in patients with diabetes or moderate-to-severe kidney impairment.
Contraindications
Karvea must not be used in the following situations:
- Pregnancy: Irbesartan is contraindicated throughout pregnancy. Use during the second and third trimesters has been associated with foetal renal failure, oligohydramnios (low amniotic fluid), skull ossification defects, limb contractures, lung hypoplasia, and neonatal death. If pregnancy is detected, Karvea should be discontinued as soon as possible.
- Hypersensitivity: Patients with a known allergy to irbesartan or any of the excipients in the tablet formulation should not take this medication.
- Concomitant use with aliskiren: In patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²), the combination of Karvea with aliskiren-containing products is contraindicated due to an increased risk of hyperkalaemia, hypotension, and renal impairment.
- Severe hepatic impairment: There is limited clinical experience in patients with severe hepatic impairment, and the use of irbesartan is not recommended in this population.
Warnings and Precautions
Several important warnings apply to the use of Karvea. Patients should discuss these with their healthcare provider before starting treatment:
Do not combine Karvea with an ACE inhibitor or aliskiren (dual RAAS blockade). Clinical trials, including ONTARGET and VA NEPHRON-D, have demonstrated that dual blockade of the renin-angiotensin system increases the risk of hypotension, hyperkalaemia, and changes in renal function (including acute renal failure) compared with monotherapy. The ESC/ESH guidelines recommend against dual RAAS blockade.
- Volume depletion and dehydration: Patients who are volume-depleted (e.g., due to diuretic therapy, dietary salt restriction, dialysis, diarrhoea, or vomiting) may experience symptomatic hypotension after starting Karvea. Volume depletion should be corrected before initiating therapy, or treatment should be started at a lower dose.
- Renal impairment: Deterioration of renal function may occur in susceptible individuals. Patients with renal artery stenosis (unilateral or bilateral) are at particular risk. Regular monitoring of serum creatinine and potassium is recommended.
- Hyperkalaemia: Irbesartan can elevate serum potassium levels, particularly in patients with renal impairment, diabetes, or those taking potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium. Regular monitoring of potassium levels is advised.
- Aortic or mitral valve stenosis / hypertrophic cardiomyopathy: As with all vasodilators, special caution is warranted in patients with haemodynamically significant aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy.
- Primary aldosteronism: Patients with primary aldosteronism generally do not respond well to antihypertensive drugs acting through the renin-angiotensin system. The use of Karvea is not recommended in these patients.
Pregnancy and Breastfeeding
Karvea is classified as a pregnancy category D medication (evidence of human foetal risk). It must not be used at any stage of pregnancy. If a patient becomes pregnant while taking Karvea, the medication should be stopped immediately and the patient should seek medical advice. Alternative antihypertensive treatments with an established safety profile during pregnancy – such as labetalol, methyldopa, or nifedipine – should be initiated.
There is limited information on the use of irbesartan during breastfeeding. It is not known whether irbesartan passes into human breast milk, although it is excreted in the milk of lactating rats. Due to the potential for adverse effects on the nursing infant, the use of Karvea during breastfeeding is not recommended. Healthcare providers should consider either discontinuing breastfeeding or discontinuing Karvea, taking into account the importance of the drug to the mother.
Women who are planning a pregnancy should be switched to an alternative antihypertensive medication before conception. If pregnancy is diagnosed while taking Karvea, discontinue the drug immediately and consult your physician. Exposure during the first trimester carries a lower risk than the second or third trimesters, but no stage of pregnancy is considered safe.
How Does Karvea Interact with Other Drugs?
Karvea can interact with several medications, most notably lithium, potassium-sparing diuretics, NSAIDs, ACE inhibitors, and aliskiren. These interactions may increase the risk of hyperkalaemia, kidney impairment, or excessive blood pressure lowering. Always inform your doctor and pharmacist about all medications you are taking.
Drug interactions with irbesartan are primarily related to its effects on the renin-angiotensin-aldosterone system, potassium homeostasis, and renal function. While irbesartan is metabolised by CYP2C9, clinically significant pharmacokinetic interactions are relatively uncommon. However, pharmacodynamic interactions – where two drugs have additive or synergistic effects – are an important clinical concern.
Major Interactions
| Drug / Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Lithium | Increased lithium levels and toxicity risk due to reduced renal lithium clearance | Monitor lithium levels closely. Combination not recommended unless no alternative exists. |
| Aliskiren | Dual RAAS blockade increases risk of hyperkalaemia, hypotension, and renal impairment | Contraindicated in patients with diabetes or GFR <60 mL/min. Avoid in all patients. |
| ACE inhibitors | Dual RAAS blockade with increased adverse renal and cardiovascular events | Do not combine. Use one or the other, not both. |
| NSAIDs (e.g., ibuprofen, naproxen, diclofenac) | May reduce antihypertensive effect and increase risk of acute kidney injury and hyperkalaemia | Use with caution. Ensure adequate hydration. Monitor renal function and potassium. |
| Potassium-sparing diuretics (e.g., spironolactone, eplerenone, amiloride) | Additive risk of hyperkalaemia | Monitor serum potassium regularly. Use lowest effective doses. |
Minor Interactions
| Drug / Class | Interaction Effect | Clinical Recommendation |
|---|---|---|
| Potassium supplements / salt substitutes | Increased risk of hyperkalaemia | Avoid unless directed by a physician. Monitor potassium levels. |
| Trimethoprim | Additive hyperkalaemia risk (trimethoprim has amiloride-like properties) | Monitor potassium during concomitant use. |
| Thiazide diuretics (e.g., hydrochlorothiazide) | Additive blood pressure-lowering effect (used therapeutically in fixed-dose combinations) | Generally safe and effective. CoAprovel (irbesartan/HCTZ) is an approved combination. |
| Digoxin | No clinically significant pharmacokinetic interaction | No dose adjustment required. |
| Warfarin | No clinically significant pharmacokinetic interaction | No dose adjustment required. Standard INR monitoring. |
Irbesartan does not inhibit or induce CYP3A4, CYP1A2, CYP2A6, CYP2B6, CYP2D6, or CYP2E1 to a clinically significant degree. It is primarily metabolised by CYP2C9, but no clinically relevant interactions with CYP2C9 substrates (such as warfarin or tolbutamide) have been observed in studies. However, as genetic polymorphisms in CYP2C9 can affect irbesartan metabolism, patients who are poor metabolisers of CYP2C9 may have higher irbesartan exposure.
What Is the Correct Dosage of Karvea?
The usual starting dose of Karvea for adults with hypertension is 150 mg once daily, which may be increased to 300 mg once daily for optimal blood pressure control. For diabetic nephropathy, the recommended maintenance dose is 300 mg once daily. Karvea can be taken with or without food, at any time of day, but consistency is recommended.
Adults
Hypertension
Starting dose: 150 mg once daily
Maintenance dose: 150–300 mg once daily
Maximum dose: 300 mg once daily
Patients who are volume-depleted (e.g., from diuretic use or dietary salt restriction) should start at a lower dose of 75 mg once daily. The dose should be titrated based on blood pressure response, typically assessed at 2–4 week intervals. The full antihypertensive effect is usually achieved within 4–6 weeks.
Diabetic Nephropathy in Type 2 Diabetes
Recommended maintenance dose: 300 mg once daily
The IDNT trial demonstrated that 300 mg was the effective dose for renal protection. Therapy should be initiated at 150 mg once daily and increased to 300 mg as the preferred maintenance dose for renoprotection.
| Patient Group | Starting Dose | Usual Dose | Maximum Dose |
|---|---|---|---|
| Adults – Hypertension | 150 mg once daily | 150–300 mg once daily | 300 mg/day |
| Volume-depleted patients | 75 mg once daily | 150–300 mg once daily | 300 mg/day |
| Diabetic nephropathy (type 2) | 150 mg once daily | 300 mg once daily | 300 mg/day |
| Renal impairment (mild–moderate) | No adjustment needed | 150–300 mg once daily | 300 mg/day |
| Haemodialysis patients | 75 mg once daily | Individualised | 300 mg/day |
Children
The safety and efficacy of Karvea in children and adolescents under 18 years of age have not been established. Irbesartan is not recommended for use in paediatric patients. If antihypertensive treatment is needed in children, other medication classes with established paediatric data should be considered, and the child should be managed by a paediatric specialist.
Elderly
No initial dose adjustment is required for elderly patients. However, as elderly individuals are more likely to have reduced renal function and volume depletion, treatment should be initiated with care. Blood pressure and renal function should be monitored regularly, particularly during the first weeks of treatment. In patients over 75 years of age, clinical experience is more limited, and a conservative approach to dose titration is advisable.
Missed Dose
If you miss a dose of Karvea, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one. If you frequently forget doses, consider setting a daily alarm or using a pill organiser to help maintain a consistent routine. Consistent daily dosing is important for maintaining stable blood pressure control throughout the 24-hour period.
Overdose
In the event of an overdose of Karvea, the most likely symptoms are hypotension (abnormally low blood pressure) and tachycardia (rapid heart rate). Bradycardia (slow heart rate) may also occur. Treatment of overdose is symptomatic and supportive. The patient should be placed in the supine position with legs elevated to promote venous return. Intravenous fluids should be administered for volume expansion. Irbesartan is not removed by haemodialysis. In case of suspected overdose, seek immediate medical attention or contact your regional poison control centre.
If you or someone else has taken more Karvea than prescribed, seek emergency medical help immediately. Symptoms of overdose may include severe dizziness, fainting, or an unusually fast or slow heartbeat. Call your local emergency number or poison control centre.
What Are the Side Effects of Karvea?
Karvea is generally well tolerated. The most commonly reported side effects include dizziness, nausea, and fatigue. Unlike ACE inhibitors, dry cough is uncommon with irbesartan. Serious but rare side effects include hyperkalaemia (elevated potassium), renal impairment, and angioedema. Report any unusual symptoms to your doctor promptly.
Like all medications, Karvea can cause side effects, although not everybody gets them. Clinical trials involving thousands of patients have established a comprehensive safety profile for irbesartan. The following frequency categories are based on data from clinical trials and post-marketing surveillance:
Common
- Dizziness, including dizziness on standing (orthostatic dizziness)
- Nausea and vomiting
- Fatigue
- Musculoskeletal pain (muscle or joint pain)
- Elevated blood creatine kinase levels
Uncommon
- Orthostatic hypotension (drop in blood pressure when standing)
- Tachycardia (rapid heartbeat) or flushing
- Cough
- Diarrhoea, dyspepsia (indigestion), or dysgeusia (altered taste)
- Chest pain
- Hyperkalaemia (elevated blood potassium)
- Elevated liver enzymes or raised blood urea nitrogen
- Sexual dysfunction
Rare
- Angioedema (swelling of the face, lips, tongue, or throat)
- Hepatitis (inflammation of the liver)
- Jaundice (yellowing of the skin or eyes)
- Tinnitus (ringing in the ears)
- Headache
- Thrombocytopenia (low platelet count)
Not Known
- Hyperkalaemia (potentially severe elevation of potassium, especially in at-risk groups)
- Impaired renal function, including cases of renal failure in at-risk patients
- Hyponatraemia (low blood sodium)
Most side effects of Karvea are mild to moderate in severity and tend to be transient. In clinical trials, the incidence of side effects with irbesartan was similar to placebo, and the discontinuation rate due to adverse events was low (approximately 3.3% for irbesartan versus 4.5% for placebo in the pivotal hypertension trials).
Dizziness is more likely to occur at the start of treatment or when the dose is increased, and usually resolves as the body adjusts to the medication. Getting up slowly from a sitting or lying position can help reduce dizziness. If dizziness persists or is severe, contact your doctor.
Seek urgent medical care if you experience signs of angioedema (sudden swelling of the face, lips, tongue, or throat, with difficulty breathing or swallowing), signs of severe allergic reaction (widespread rash, itching, wheezing), symptoms of severely low blood pressure (fainting, extreme dizziness, confusion), or signs of high potassium (irregular heartbeat, muscle weakness, numbness or tingling).
How Should You Store Karvea?
Store Karvea in its original packaging at room temperature below 30°C. Keep it out of the reach and sight of children. Do not use after the expiry date printed on the packaging.
Karvea tablets should be stored in the original blister pack or container to protect them from moisture. Do not store above 30°C (86°F). There are no special storage requirements regarding refrigeration; room temperature storage is appropriate. Keep the packaging closed until you need to take a dose.
As with all medications, Karvea should be kept out of the reach and sight of children. Do not use the tablets after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of that month. Do not dispose of medications via wastewater or household waste. Return unused or expired medicines to your pharmacist for safe disposal, in accordance with local regulations. This helps to protect the environment.
If you notice any visible change in the appearance of the tablets (such as discolouration, unusual odour, or crumbling), do not take them and consult your pharmacist. Do not transfer the tablets to a different container unless it is a pharmacist-supplied dosette box or pill organiser designed for short-term use.
What Does Karvea Contain?
Each Karvea tablet contains irbesartan as the active substance. The film-coated tablets are available in three strengths: 75 mg, 150 mg, and 300 mg. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, and macrogol 3000.
Active Substance
The active pharmaceutical ingredient in Karvea is irbesartan. Each film-coated tablet contains either 75 mg, 150 mg, or 300 mg of irbesartan. Irbesartan is a white to off-white crystalline powder with a molecular weight of 428.53 g/mol. Its chemical name is 2-butyl-3-[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl-1,3-diazaspiro[4.4]non-1-en-4-one.
Inactive Ingredients (Excipients)
The tablet core contains:
- Lactose monohydrate: A filler and binder (patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine)
- Microcrystalline cellulose: A filler and binder
- Croscarmellose sodium: A disintegrant that helps the tablet break apart for absorption
- Hypromellose: A binder
- Colloidal anhydrous silica (silicon dioxide): A flow agent
- Magnesium stearate: A lubricant for the tableting process
The film coating contains:
- Hypromellose: Film-forming agent
- Titanium dioxide (E171): Colourant (white)
- Macrogol 3000: Plasticiser
- Carnauba wax: Polishing agent (for the 75 mg and 150 mg tablets)
The 75 mg tablet is white, biconvex, oval-shaped, with a heart debossed on one side and the number 2771 engraved on the other. The 150 mg tablet is white, biconvex, oval-shaped, with a heart debossed on one side and the number 2772 on the other. The 300 mg tablet is white, biconvex, oval-shaped, with a heart debossed on one side and the number 2773 on the other.
Frequently Asked Questions About Karvea
Karvea (irbesartan) is used to treat high blood pressure (hypertension) and to protect the kidneys in patients with type 2 diabetes who also have high blood pressure (diabetic nephropathy). It belongs to the angiotensin II receptor blocker (ARB) class and works by relaxing blood vessels so blood can flow more easily, reducing the workload on the heart and kidneys.
The most common side effects of Karvea include dizziness (including orthostatic dizziness), nausea, vomiting, fatigue, and musculoskeletal pain. These side effects are generally mild and tend to improve with continued use. Unlike ACE inhibitors, Karvea rarely causes a dry, persistent cough. If side effects persist or worsen, consult your doctor.
No. Karvea must not be taken during pregnancy, especially during the second and third trimesters, as it can cause serious harm to the unborn baby, including kidney damage, low amniotic fluid, and bone development problems. If you become pregnant while taking Karvea, stop the medication immediately and contact your doctor. Safer alternatives for blood pressure control during pregnancy include labetalol and methyldopa.
Both Karvea (an ARB) and ACE inhibitors lower blood pressure by targeting the renin-angiotensin system, but they act at different points. ACE inhibitors block the enzyme that converts angiotensin I to angiotensin II, while Karvea blocks the receptor where angiotensin II exerts its effects. The main practical advantage is that ARBs like Karvea cause significantly less dry cough – a side effect that affects 5–20% of patients on ACE inhibitors – because ARBs do not interfere with bradykinin metabolism.
Karvea begins lowering blood pressure within 1–2 hours of the first dose. However, the maximum blood pressure-lowering effect at a given dose is typically reached after 4–6 weeks of continuous daily treatment. Your doctor may adjust your dose at 2–4 week intervals. Do not stop taking Karvea without medical advice, even if you feel well, as high blood pressure usually has no symptoms.
Alcohol can enhance the blood pressure-lowering effect of Karvea and increase the risk of dizziness, lightheadedness, and fainting. While moderate alcohol consumption is not strictly prohibited, it is advisable to limit your intake and to be aware of how you feel after drinking. Stand up slowly to reduce the risk of falls. Discuss your alcohol consumption with your doctor.
References and Sources
This article is based on the following peer-reviewed medical guidelines, clinical trials, and authoritative sources. All medical claims are supported by evidence level 1A (systematic reviews and meta-analyses of randomised controlled trials) where available.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–3104. Updated 2023. doi:10.1093/eurheartj/ehy339
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Cardiology. 2018;71(19):e127–e248. doi:10.1016/j.jacc.2017.11.006
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes (IDNT). New England Journal of Medicine. 2001;345(12):851–860. doi:10.1056/NEJMoa011303
- Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes (IRMA 2). New England Journal of Medicine. 2001;345(12):870–878. doi:10.1056/NEJMoa011489
- ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine. 2008;358(15):1547–1559. doi:10.1056/NEJMoa0801317
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2024;14(4S):e1–e314.
- World Health Organization. Hypertension Fact Sheet. WHO. 2023. Available at: who.int/news-room/fact-sheets/detail/hypertension
- European Medicines Agency. Karvea (irbesartan) – Summary of Product Characteristics. EMA. Last updated 2024.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [NG136]. NICE Guideline. 2022 update.
- British National Formulary (BNF). Irbesartan – Drug Monograph. NICE/BNF. Last updated 2025.
Medical Editorial Team
This article has been developed and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialisation in cardiology, nephrology, and clinical pharmacology. Our editorial process follows the GRADE evidence framework and adheres to the principles of evidence-based medicine.
Written by qualified medical professionals with expertise in cardiovascular medicine and clinical pharmacology, based on current international guidelines (ESC/ESH, AHA/ACC, NICE, KDIGO).
All content undergoes peer review by independent specialist physicians. No commercial funding or pharmaceutical industry sponsorship influences our editorial decisions.
We prioritise Level 1A evidence from systematic reviews and randomised controlled trials. Sources include landmark trials (IDNT, IRMA 2), WHO guidelines, and authoritative drug reference databases (BNF, EMA).
Articles are reviewed and updated regularly to reflect new clinical evidence, updated guidelines, and changes in prescribing information. Last reviewed: January 2026.